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Background: Adherence to therapy has been established for years as a critical parameter for clinical benefit in
medical oncology. This study aimed to assess, in the current practice, the influence of the socio-demographical
characteristics and the place of treatment on treatment adherence and overall survival among diffuse large B-cell
lymphoma patients.
Methods: We analysed data from 380 patients enrolled in a French multi-centre regional cohort, with diffuse large
B-cell lymphoma receiving first-line treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) or R-CHOP-like regimens. Direct examination of administrative and medical records yielded the date
of death. We studied the influence of patients’ socio-demographic characteristics and place of treatment on the
treatment adherence and overall survival, adjusted for baseline clinical characteristics. Treatment adherence was
measured by the ratio between received and planned dose Intensity (DI), called relative DI (RDI) categorized in
“lesser than 85%” and “at least 85%”.
Results: During the follow-up, among the final sample 70 patients had RDI lesser than 85% and 94 deceased.
Multivariate models showed that advanced age, poor international prognosis index (IPI) and treatment with
R-CHOP 14 favoured RDI lesser than 85%. The treatment in a public academic centre favoured RDI greater than or
equal to 85%. Poor adherence to treatment was strongly associated with poor overall survival whereas being
treated in private centres was linked to better overall survival, after adjusting for confounders. No socioeconomic
gradient was found on both adherence to treatment and overall survival.
Conclusions: These results reinforce adherence to treatment as a critical parameter for clinical benefit among
diffuse large B-cell lymphoma patients under R-CHOP. The place of treatment, but not the socioeconomic status of
these patients, impacted both RDI and overall survival
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Diffuse large B-cell lymphoma (DLBCL) is one of the most
frequent histological subtypes among Non-Hodgkin’s lymph-
omas (NHL) [1]. DLBCL course is naturally aggressive
due to rapid tumour progression, visceral propagation,
and metabolic complications related to lysis syndrome.
However, DLBCL is a chemosensitive disease for which
anthracyclin-based chemotherapy with CHOP was found
to be effective since its introduction in the late seventies
[2]. During the last decade, chemotherapy further im-
proved through the development of immunochemother-
apy consisting in the addition of rituximab (R) to CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) or CHOP-derived regimens [3,4]. R-CHOP
administered each 21 days (R-CHOP21) has become the
standard for front-line treatment for DLBCL based on
the pivotal LNH-98-5 study of the Grouped’ Etude des
Lymphomes de l’Adulte (GELA) [3]. However, some vari-
ants of treatment have been designed in order to increase
CHOP intensity by shortening the intercourse period,
such as the R-CHOP14 protocol (given each 14 days) pro-
moted by the German Lymphoma Study Group, and/or
by increasing doses such as the R-ACVBP (rituximab,
doxorubicin, cyclophosphamide, vindesine, bleomycin and
prednisone) protocol derived from the GELA studies. In
the GELA network, despite its higher toxicity compared
to CHOP, R-ACVBP has become the standard for young
patients with high international prognosis index (IPI)
scores [5]. Finally, low-intensity chemotherapy, such as
R-mini-CHOP, has been developed in elderly patients
with age older than 80 years and was found to be tolerable
and reasonably effective in this context [6].
In spite of adaptation to age and supportive care, in-
cluding widespread use of hematopoietic growth factors
(HGF), R-CHOP and R-CHOP derived protocols induce
significant toxicities with life-threatening complications,
like febrile neutropenia, sepsis and severe gastro-intestinal
toxicities. Treatment-related mortality (TRM) remains
relatively low in younger patients (2-5%) but could reach
up to 8% for patients older than 60 years-old [3,7,8]. In-
tolerance to treatment often results in reducing treatment
intensity, and consequently, non-adherence to the treat-
ment protocol. Adherence to a chemotherapy regimen
can be measured either by the ratio between the number
of cycles administered and planned, or by the relative
dose-intensity (RDI) which is the amount of drug deliv-
ered per time unit, compared to doses defined in the treat-
ment protocol [9]. Dose concession is considered as a key
issue in the treatment of patients with DLBCL [9-14].
The influence of RDI on outcome in CHOP therapy
was first described by Epelbaum and co-workers more
than 20 years ago with significant higher response rates
for DLCBL patients who presented a better adherence to
treatment [15]. Following this pioneer study, severalreports have confirmed that higher RDI correlated with
prolonged survival among NHL [11], including DLBCL
[9,10,15,16]. Other studies found that poor treatment
adherence assessed by the RDI was, besides age and IPI,
one of the most potent predictors for survival [10,12].
The introduction of rituximab at the end of the 90s has
reopened this question as two studies showed that, in
DLBCL treated with R-CHOP, treatment adherence cor-
related with prolonged survival in multivariate analysis
with several cut-offs of RDI [13,14]. Factors predicting
RDI have been already identified in at least five cohort
studies listed in a recent review. The most significant pre-
dictors were age older than 60–65 years, followed by of
the Eastern Cooperative Oncology Group performance
(ECOG) status, type of RCHOP therapy (ACVBP versus
standard CHOP), IPI and use of G-CSF [17].
Besides such parameters related to patient physical
characteristics or to the disease, the socioeconomic sta-
tus (SES) and the place of treatment might also interfere
with RDI. Indeed, some socioeconomic characteristics,
as the level of education and the occupational status,
have already been shown to be associated with treatment
access and survival among patient with NHL [18-21].
Although these disparities could not be entirely related
to chemotherapy administration, they may reflect differ-
ences in healthcare quality level and therefore, raise the
possibility that the administration of chemotherapy can
be also affected. Alternatively, since it has been shown
that the place of treatment (academic versus community
centre) may also influence overall survival of DLBCL pa-
tients [22], it could also be possible that this parameter
influences the RDI.
In this study, we investigate the adherence to chemother-
apy in current practice in a French health care system in a
prospective cohort of patients treated for DLBCL with
R-CHOP or R-CHOP derived regimens. More specific-
ally, we study treatment adherence determinants by distin-
guishing the clinical characteristics, the socio-demographical
characteristics of patients including their socioeconomic
status, the place of treatment. Finally, we study the associ-
ation between RDI and mortality.
Methods
Study design and population
This work is based on data from an ongoing prospective
cohort of DLBCL patients in the French Midi-Pyrénées
region, in the southwest of the country: the AMARE
cohort. Patients were included if they received first-line
treatment for DLBCL with R-CHOP or R-CHOP-like
regimens from November 2006 without age restriction,
in the main centres covered by the regional cancer net-
work. Patients were excluded if they displayed central
nervous system involvement, HIV infection, solid organ
transplantation or previous documented indolent NHL.
Borel et al. BMC Cancer  (2015) 15:288 Page 3 of 11All patients signed informed consent before inclusion in
this network. The study was approved by the local eth-
ical committee of the Toulouse University Hospital.
Data collection
Data were collected by one person through direct exam-
ination of administrative and medical records of the 418
patients treated between November 2006 and June 2011
(last follow up in June 2014). During the follow-up, infor-
mation was gathered regarding treatment-related events
and vital status, including the date of the events.
Socio-demographical characteristics of patients
Patients’ characteristics included severe comorbidity (none;
at least one among chronic or viral hepatitis, cardiovascu-
lar or metabolic disease, autoimmune disease or cancer)
and social characteristics at diagnosis. The last one encom-
passed occupational status (active; inactive) and marital
status (alone; not alone) at diagnosis. In addition, we used
the European ecological deprivation index (EDI) built from
patients’ addresses as a proxy of their individual socioeco-
nomic status [23]. The geographical units used were IRIS
as defined by the National Institute for Statistics and
Economic Studies (INSEE), whereby an IRIS represented
the smallest geographical census unit available in France,
including approximately 2000 individuals with relatively
homogeneous social characteristics. The regional capital
and other major towns are divided into several IRIS and
small towns form one IRIS. A score of social deprivation
has been attributed to each IRIS: the higher the score, the
higher the level of social deprivation. We used quintile of
social deprivation as a proxy of the individual socioeco-
nomic status, the highest quintile corresponding to the
lowest socioeconomic status [23].
Clinical characteristics
At diagnosis were collected: age (coded in tertile in our
models), gender, the presence or absence of systemic (B)
symptoms; the Ann Arbor stage (localized (Ann Arbor
stage I or II) or advanced (Ann Arbor stage III or IV);
the serum Lactate Dehydrogenase (LDH) concentration
(normal or elevated); the ECOG performance status (PS)
(PS = 0 or 1 (good); PS = 2, 3, or 4 (poor)) [24] and the
IPI [25,26]. As it already accounted for each of the three
former prognosis factors completed by the presence of
more than one extra nodal site and age older than 60
years-old, the IPI score was used in our analyses in
order to limit the number of variables to adjust for in
statistical models and coded in three prognostic groups
as suggested by Sehn et al. for DLBCL patients treated
with R-CHOP: very good for IPI = 0, good for IPI =1
or 2 and poor for IPI = 3, 4 or 5 [27]. Regimens have
already been described elsewhere [3,5,8,28]. Treatment
followed the GELA recommendations or trials relevantto this period. Supportive care consisted of valacyclovir,
sulfamethoxazole-trimethoprim and granulocyte colony-
stimulating factor (G-CSF) primary prophylaxis for all.
Place of treatment
The treatment centres encompassed six public centres
(1 academic and 5 non-academic hospitals) and three
private centres which were categorized as private centres,
public academic centres (Toulouse University Medical
Centres (TUMC)), or public community hospitals.
Adherence to treatment
For each patient, adherence to treatment was assessed
using the ratio between received and planned dose inten-
sity as described by Epelbaum et al. [9]. For each patient,
dose intensity (DI) was calculated, by direct examination
of pharmacist records and by dividing the total actual dose
of each drug by the time needed to deliver it. The expres-
sion of the actual DI as a fraction of the stated dose was
defined as relative DI (RDI). In this study, we calculated
RDI for the principal drugs, i.e. cyclophosphamide and
doxorubicin. As the classification of patients between the
groups “poor adherence” and “good adherence” was simi-
lar for the two drugs, only those for doxorubicin are
shown. In the RDI calculation, we considered the follow-
ing planned dose intensities for doxorubicin: 8 cycles
of 21 days with 50 mg/m2 for R-CHOP21 and R-CHVP
(rituximab, cyclophosphamide, doxorubicin, etoposide,
prednisone), 8 cycles of 14 days with 50 mg/m2 for
R-CHOP14, 8 cycles of 21 days with 25 mg/m2 for
R-miniCHOP and R-miniCHVP, 4 cycles of 14 days with
75 mg/m2 for R-ACVBP. We used a cut-off value reduc-
tion of 15%, based on the study of Lyman et al. [29].
Survival
Overall Survival (OS) was calculated from the first day
of the first chemotherapy until death of any cause. These
data were found in the medical records during the
follow-up visits at the centres followed in the study.
Statistical analysis
Patients included in the cohort were described by quin-
tile of social deprivation index to give an overview of the
social distribution of the characteristics related to the dis-
ease, the patient and care modalities. Then, we built multi-
variate models for analyzing RDI (RDI < 85% or ≥85%)
and survival including all variables associated with these
outcomes in bivariate analyses at the threshold of 0.2 (data
not shown). A logistic regression model was performed to
identify determinants of RDI. Regarding survival analyses,
Kaplan-Meier survival curves were plotted and compared
using the log-rank test. Then a Cox model was performed
to identify determinants of survival, including RDI. For all
models, conditions of application and models fit were
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model and by analysing Schoenfeld residuals for the Cox
model. As the proportional hazard assumption was vio-
lated for treatment adherence, we used a Cox model with
time-varying coefficient. All the analyses were done by
using STATA release 12 (StataCorp LP, College Station,
TX, USA).
Results
Among the 418 patients initially included in this study, 2
deceased before starting treatment and 4 had no data
regarding RDI. Poor adherence to treatment concerned
17.5% (72/412) of all treated patients with data on ad-
herence to treatment. The baseline characteristics of pa-
tients features are presented in Tables 1, 2 and 3 for the
clinical characteristics, socio-demographical profiles and
the place of treatment. Among these patients, 16 pa-
tients had no IPI score. Fifteen patients presented an in-
complete or incorrect home address which did not allowTable 1 Clinical characteristics of the 412 DLBCL patients with
comparisons between RDI groups
Total
n %
Gender Male 222 53
Female 190 46
Age <59 y 146 35
59 - 73 y 135 32
>73 y 131 31
Comorbidity none 161 39
at least 1 251 60
Standard International
prognostic index (sIPI)




LDH normal 197 47
elevated 215 52
B signs absence 336 81
presence 76 18
Ann Arbor Stage I-II 142 34
III-IV 270 65
Performance status PS = 0-1 385 93
PS = 2-4 27 6.6
Regimens R- CHOP 21 or R-CHVP 223 54
R- CHOP 14 34 8.3
R- ACVBP 45 10
R-mini CHOP or R-mini CHVP 100 24
other 10 2.4
In bivariate analyses, p-values derived from the chi2 test a or the Fisher Exact test b
DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; LDH: lactate dehyfinding the corresponding IRIS or the EDI score, and
one patient had no data for both IPI and EDI. The final
sample used for multivariate models included 380 pa-
tients (91% of the total sample). During the follow-up,
94 patients died and 70 had a treatment adherence (RDI
< 85%). The flowchart is presented in Figure 1.
The results of the bivariate analyses in Tables 1, 2 and
3 shown that RDI < 85% was associated with age, comor-
bidity, LDH, IPI, Ann Arbor Stage, type of treatment, so-
cioeconomic status and place of treatment. Table 4
presents the results of the multivariate model studying
the effects of clinical characteristics, socio-demographic
profiles and place of treatment on the risk of having a
poor RDI. Regarding clinical characteristics, poor RDI
was favoured by advanced age, high risk IPI and treat-
ment with R-CHOP 14. For socio-demographic charac-
teristics, no socioeconomic gradient was found but we
observed a protective effect of being in intermediate
level compared to the highly favoured level. Finally, wedata on RDI included in the AMARE cohort study and
RDI < 85% (n = 72) RDI ≥ 85% (n = 340) P valuea
n % n %
.9 34 47.2 188 55.3 0.212
.1 38 52.8 152 44.7
.4 14 19.4 132 38.8 <0.001
.8 20 27.8 115 33.8
.8 38 52.8 93 27.4
.1 22 30.6 139 40.9 0.103
.9 50 69.4 201 59.1
.6 5 6.9 51 15 <0.001
.7 29 40.3 188 55.3
.6 37 51.4 85 25
1 1.4 16 4.7
.8 27 37.5 170 50 0.054
.2 45 62.5 170 50
.6 61 84.7 275 80.9 0.445
.5 11 15.3 65 19.1
.5 15 20.8 127 37.4 0.007
.5 57 79.2 213 62.7
.5 69 95.8 316 92.9 0.598 b
3 4.2 24 7.1
.1 28 38.9 195 57.4 <0.001 b
10 13.9 24 7.1
.9 3 4.2 42 12.4
.3 30 41.7 70 20.6
1 1.4 9 2.7
when the expected frequencies were less than 5.
drogenase.
Table 2 Socio-demographic characteristics of the 412 DLBCL patients with data on RDI included in the AMARE cohort
study and comparisons between RDI groups
Total RDI < 85% (n = 72) RDI ≥ 85% (n = 340) P valuea
n % n % n %
Occupational status active 123 29.9 22 30.6 101 29.7 0.861
inactive/retired 268 65.1 46 63.9 222 65.3
missing 21 5.1 4 5.6 17 5
Cohabiting status not alone 253 61.4 41 56.9 212 62.4 0.271
alone 125 30.3 26 36.1 99 29.1
missing 34 8.3 5 6.9 29 8.5
Socioeconomic status
(quintile of EDI national scores)
1: highly favoured 74 18.0 12 16.7 62 18.2 0.101
2: favoured 72 17.5 20 27.8 52 15.3
3: intermediate level 96 23.3 11 15.3 85 25
4: deprived 89 21.6 17 23.6 72 21.2
5: highly deprived 65 15.8 11 15.3 54 15.9
missing 16 3.9 1 1.4 15 4.4
In bivariate analyses, p-values derived from the chi2 test a.
DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; EDI: European deprivation index.
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tect against poor adherence to treatment.
For survival analyses, the median follow-up was 994 days
and the maximum length of follow-up was 2363 days. The
year of diagnosis was not associated with overall survival
(data not shown). As shown in the Kaplan-Meier’s curves
plotted in Figure 2, poor RDI was associated with reduced
overall survival (a reduction of about 25% at 24 month).
The place of treatment seemed also influence overall sur-
vival with a reduced survival in community hospitals com-
pared to private and academic centres. However, we found
no socioeconomic gradient in overall survival. Analyses
of Schoenfeld’s residuals showed a violation in the pro-
portional hazard assumption for RDI (data not shown).
Figure 2A suggests indeed that RDI < 85% more negatively
influenced overall survival during the first 24-month
period. That is why we introduced an interaction term be-
tween RDI and time in the Cox multivariate model noted
as RDI*time in Table 5. Poor overall survival was associ-
ated with poor RDI. The significance of the RDI*time vari-
able means that the negative effect on overall survival of
having a RDI < 85% decreased with duration from the
chemotherapy initiation. Complementary analyses showedTable 3 Place of treatment of the 412 DLBCL patients with da
comparisons between RDI groups
Total
n %
Place of treatment Private centres 104 25.2
TUMC 180 43.7
Community hospitals 128 31.1
In bivariate analyses, p-values derived from the chi2 test a.
DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; TUMC: Toulousethat RDI < 85% reduced overall survival only during the
first 24 month after treatment initiation (adjusted hazard
ratio [95% confidence interval] = 3.23 [1.84; 5.69]). Table 5
shows no effect of the socioeconomic status on overall
survival. Moreover, overall survival was higher for patients
cared for in private hospitals compared to public aca-
demics or community centres (p-values = 0.068 and 0.075
respectively). Table 5 shows also poorer survival among
patients with advanced age and poor IPI. Women had a
better overall survival. No differences were found between
chemotherapy regimens.
Discussion
In this population-based prospective cohort study, we
found poor adherence, defined as RDI < 85%, in 17.5% of
the treated patients (72/412). We showed that advanced
age, poor IPI and treatment with R-CHOP 14 favoured
RDI < 85%, as expected. Treatment in the academic centre
TUMC was associated with RDI ≥ 85%. The results of our
survival analyses designated poor adherence to treatment
as strongly associated with poor overall survival independ-
ent of patients’ age, gender, socioeconomic status, comor-
bidity, IPI score, chemotherapy regimens and the place ofta on RDI included in the AMARE cohort study and
RDI < 85% (n = 72) RDI ≥ 85% (n = 340) P valuea
n % n %
22 30.6 82 24.1 0.002
18 25 162 47.7
32 44.4 96 28.2
university medical centre.
Figure 1 Flowchart.
Table 4 Factors associated with receiving a relative dose-intensity lower than 85% - results of a multivariate logistic
regression model (n = 380)
Odds ratios p-value [95% Confidence Interval]
Gender Male 1
Female 1.32 0.361 [0.73; 2.37]
Agea <59 y 1
59 - 73 y 1.06 0.902 [0.41; 2.77]
>73 y 4.42 0.019 [1.27; 15.35]
Socioeconomic statusb (quintile of EDI national scores) 1: highly favoured 1
2: favoured 1.49 0.387 [0.60; 3.67]
3: intermediate level 0.32 0.025 [0.12; 0.86]
4: deprived 0.79 0.625 [0.31; 2.01]
5: highly deprived 0.72 0.526 [0.26; 1.98]
Comorbidity none 1
at least 1 1.13 0.704 [0.59; 2.18]
Standard International prognostic indexc (sIPI) very good 1
good 1.32 0.612 [0.45; 3.86]
poor 4.60 0.008 [1.48; 14.30]
Chemotherapy regimensd R- CHOP 21 or R-CHVP 1
R- CHOP 14 7.65 0.001 [2.35; 24.92]
R- ACVBP 1.30 0.737 [0.15; 6.06]
R-miniCHOP or R-mini CHVP 0.66 0.429 [0.24; 1.87]
other 0.09 0.046 [0.01; 0.96]
Place of treatmente Private centres 1
TUMC 0.23 0.003 [0.09; 0.60]
Community hospitals 1.11 0.780 [0.55; 2.23]
Notes a, b, c, d, and e indicate the global p-value; a: p = 0.027; b: p = 0.025; c: p < 0.001; d: p = 0.002; e: p = 0.002.
DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; EDI: European deprivation index; TUMC: Toulouse university medical centre.
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Figure 2 Kaplan-Meier survival estimates curves stratified by relative dose intensity (A), place of treatment (B), standard international prognostic
index (C) and quintile of social deprivation (D).
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tres were likely to have a better survival that those treated
in public community hospitals and academic centre, after
adjusting for confounders. Patients' socioeconomic status
assessed by the level of social deprivation of their living
area at the time of diagnosis had no effect on neither
adherence to treatment nor overall survival.
In this study, we selected patients from the regional
cancer network and we cannot generalise our results to
the national level. At the regional level, we focused on
the main centres covered by the network and thus we
may have lost in representativeness. About 10% of the
initial sample was excluded from our analyses because of
missing data. In addition, the time period for including
patients was almost five years. As a consequence, pa-
tients included at the end of the inclusion period may be
more prone to be censored and thus they have less time
to reach the event of interest than those included at the
beginning of the period. Moreover, we had no data on
what led to reduction in RDI and we could not know if
it was a patient’s refusal or trepidation to receive treat-
ment because of side effect, a physician’s decision in acase of a frail patient or a protocol-driven decision. How-
ever, this study was based on population data which should
well reflect routine practice. This study deals with both
medical and non-medical determinants of the treatment
adherence and overall survival among patients treated for
DLBCL in France. Data collection was prospective and
about 90% of the total sample had complete data. Moreover,
our models included patients’ socioeconomic status assessed
by a European ecological index of social deprivation used
as a proxy of the individual status.
Adherence to therapy has been established for years as
a critical parameter for clinical benefit in medical oncol-
ogy. This statement was established two decades ago for
conventional chemotherapy in breast cancer [30,31] and
lymphoma patients [32]. In the present study, we consid-
ered adherence to chemotherapy from an ecological point
of view as we assume that adherence may be influence not
only by characteristics of the individual patient, but also
by factors within the patient's environment, or so-called
system level factors. In an ecological model, patients' be-
haviour may be influenced by factors at the patient-level,
micro- (provider and social support), meso- (health care
Table 5 Factors associated with overall survival - results of a multivariate Cox regression model with the relative
dose-intensity entered as a time dependent variable (n = 380)
Hazard ratio p-value [95% Confidence interval]
Gender Male 1
Female 0.52 0.003 [0.34; 0.80]
Agea <59 y 1
59 - 73 y 1.77 0.153 [0.81; 3.88]
>73 y 2.57 0.070 [0.92; 7.15]
Socioeconomic statusb (quintile of EDI national scores) 1: highly favoured 1
2: favoured 0.91 0.783 [0.47; 1.78]
3: intermediate level 1.46 0.242 [0.78; 2.73]
4: deprived 0.61 0.171 [0.30; 1.24]
5: highly deprived 0.74 0.429 [0.36; 1.55]
Comorbidity none 1
at least 1 0.74 0.224 [0.46; 1.20]
Standard International prognostic indexc (sIPI) very good 1
good 1.30 0.559 [0.54; 3.15]
poor 2.61 0.041 [1.04; 6.57]
Chemotherapy regimensd R-CHOP21 or R-CHVP21 1
R- CHOP 14 0.57 0.246 [0.22; 1.48]
R- ACVBP 0.97 0.956 [0.32; 2.90]
R-mini CHOP or R-mini CHVP 1.94 0.122 [0.84; 4.48]
other 1.49 0.516 [0.45; 4.99]
Relative dose-intensity (RDI) RDI ≥85% 1
RDI <85% 3.89 <0.001 [1.86; 8.14]
Place of treatmente Private centres 1
TUMC 1.88 0.068 [0.95; 3.71]
Community hospitals 1.75 0.075 [0.95; 3.25]
Time dependant variables RDI * Time 0.998 0.024 [0.997; 0.999]
Notes a, b, c, d, and e indicate the global p-value; a: p = 0.176; b: p = 0.083; c: p = 0.007; d: p = 0.338; e: p = 0.133.
RDI * Time is the interaction term between RDI and time in the Cox multivariate model.
DLBCL: diffuse large B-cell lymphoma; RDI: relative dose intensity; EDI: European deprivation index; TUMC: Toulouse university medical centre.
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our study, about 17.5% of the total sample had less than
85% of the RDI. This relatively small proportion of patient
with poor adherence to treatment may be explained as the
use of G-CSF was widespread in our practices (data not
shown), considering that prophylactic GCSF use is associ-
ated with increased RDI [29]. Our results suggest a strong
effect of advanced age, treatment and poor IPI on RDI.
These results are in agreement with the factors identified
to be related to low RDI listed in Wildiers and Reiser’s re-
view which encompasses increased age (>60 years), ECOG
status, stage or IPI score and more occasionally, the type
of treatment (ACVBP, CHOP14) or the use of G-CSF (sec-
ondary or primary prophylaxis) [17]. Our results have also
pointed out a protector effect of being treated in the aca-
demic centre TUMC. Understanding the factors unique to
this centre are key to revealing potential pathways thoughwhich RDI may be affected. A higher treatment adherence
in TUMC may translate a higher experience of the med-
ical team in dealing with side-effects and more complex
case and feeling comfortable with maintaining the treat-
ment despite these. In addition in this centre, DLBCL
patients benefit from a telephone-based intervention
by an oncology-certified nurse which consists of system-
atic calls to the patients twice a week during treatment
and the collection of clinical and biological observations.
The information is then forwarded to the oncologist,
and corresponding interventions are performed [34]. As
R-CHOP is administered through intra-venous route, it
should not be influenced by patients’ attitude although the
telephone-based intervention might improve the patient-
physician relationship and patient’s positive appraisal of
the treatment centre which have been pointed out as im-
portant factors in adherence to treatment [35]. However,
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in TUMC improved the management of side effects and
secured the whole treatment, encouraging physicians to
preserve dose-intensity. Moreover, we assume that this
telephone-based intervention might improve physician
adherence by increasing patients’ information and
therapeutic education. This “physician non adherence”
encompasses non adherence to recommendations, dose or
temporal concession due to documented toxicity in agree-
ment with recommendations, but also physician individual
decision [36]. The latter had not been thoroughly in-
vestigated, essentially because it resides in the privacy
of oncology practice. Indeed, it integrates various med-
ical, psychological and social factors related to the patient
(like the age) but also to the physician [37]. In the present
study, the absence of data regarding what led to reduction
in RDI limited our capability to interpret these results
regarding adherence to treatment. Further studies are
needed to disentangle which causes of RDI reduction may
be attributable to the physician and to the patient. Such
studies should not only look for clinical factors, classically
identified as determinant of RDI [38], but also for non-
medical characteristics of patients and their environment.
The impact of RDI on outcome in lymphomas treated
with CHOP and related regimens, has been investigated
before the introduction of rituximab [9-11,15,16]. Since
the introduction of rituximab at the end of the 90s, some
studies have supported the association between RDI and
patient outcome but they were based on analyses of rela-
tively small study samples [13,14]. To our knowledge, the
present study is the first to explore the association be-
tween RDI and OS in the Rituximab era in a larger scale
study sample while studying non-medical potential deter-
minants of RDI, in particular the role of some socioeco-
nomic factors and the place of treatment. In the present
study based on a larger sample, our results suggest a
strong association between poor adherence to treatment
and the overall survival with an overall mortality almost
four-times greater among patients with RDI < 85% than
among those with RDI ≥ 85%. This association was lost
after about two-years after the treatment initiation. This
may reflect the fact that, for a patient newly treated for
DLBCL, the risk of dying from a cause related either to
his disease or the treatment diminishes with time since
the treatment initiation due to the competition with the
risk of dying from other causes unrelated to the disease
over time. The results of a recent study published by
Maurer et al. tended to support this observation as they
found no difference in overall survival between DLBCL
patients achieving 24 months of event-free survival from
diagnosis and the age- and sex-matched general popula-
tion [39]. The models we used in the present study were
all adjusted for baseline IPI scores which lessened the risk
of a reverse causation bias between in interpreting therelationship between RDI and overall survival. Indeed, a
high IPI score may be considered as risk factor of pejora-
tive disease evolution by including the stage of the disease
and the presence of more than one extra nodal site. In the
main analysis as well as in sensitivity analyses, the hazard
ratio assessing the association between RDI and overall
survival remained stable after adjusting for IPI and con-
founders suggesting no major confounding bias (data not
shown). Additional information about the causes of dose
concession and delay in treatment would have been in-
formative but at present these data are not available.
A major concern of modern oncology lies in applying
evidence-based medicine to routine medical practice in
small scale private centres or community hospitals. In
2009, a study among lymphoma patients showed that treat-
ment in rural community hospitals was associated with
poorer overall survival than treatment in academic centres,
whatever the geographical location and patients’ risk-profile
with the exception of high-risk patient among whom urban
academic centres was associated with the best outcome
[22]. A more recent study among DLBCL patients pointed
out the poorer overall survival of patients living in small
or medium urban area compared to those living in rural
or large urban areas [40]. In our study, we did not provide
direct information regarding spatial disparities of patients’
outcomes as we focused on place of treatment that was
academic centre, community hospitals or private centres.
We showed that patients treated in private centres tended
to have a better overall survival than those treated in pub-
lic centres, academic or not (global p-value for the place
of treatment variable, p = 0.133). This may reflect an un-
equal repartition of patients between the different types of
healthcare centres which, in the private sector, may lead
to an underrepresentation of high-risk-of-dying-patients.
However, multivariate analyses adjusted for comorbidities
and IPI showed no interaction between these variables
and the care modalities. Another explanation may arise
from the geographical distribution of the healthcare cen-
tres in the region corresponding roughly to academic cen-
tres in large urban areas, private centres in large and
medium urban areas and the community health centres in
small urban and rural areas. Further investigations based
on complementary data for the characterisation of the
spatial and structural environment of patients would be
necessary to formally test these hypotheses. This is the
purpose of an ongoing project.
Regarding the role of patients’ socioeconomic status, we
found a protector effect of the intermediate socioeconomic
level against poor treatment adherence. More data would
be need concerning the place of residence or the occupa-
tion to help us in the interpretation of this result. Finally,
we found no association between patients’ socioeconomic
status assessed by the European ecological deprivation
index (EDI) of the living area at diagnosis and overall
Borel et al. BMC Cancer  (2015) 15:288 Page 10 of 11survival in contrast with studies supporting social inequal-
ities in survival and treatment of Non-Hodgkin’s lymph-
omas [19-21]. A possible explanation of the absence of
socioeconomic gradient in overall survival may arise from
the fact that the cohort was constituted by patients treated
for DLBCL with the standard therapy. Indeed, the selection
of such a population allows to observe patients only once
they enter to the healthcare system but does not account
for those who encountered difficulties in access to primary
care which is a critical step in the healthcare trajectory of
cancer patients [41,42]. In our study sample, we observed
no association between patients’ IPI at diagnosis and their
socioeconomic status suggesting that no social gradient in
the distribution of this characteristic in our sample (data
not shown). Another element which may explain the ab-
sence of effect of patients’ socioeconomic status is the way
in which healthcare is organized in France. The policy of
the regional cancer network dedicated to cancer patients,
including haematological malignancies, dictates that all
e-medical files are systemically screened by disease-specific
boards constituted by university hospital staff members.
Thus, our patients may have benefited from the expertise
of the university hospital staff, independent of their socio-
economic status or their living areas. These results suggest
that the French healthcare system is doing fairly well in
absorbing the social inequalities in health among patients
treated for DLBCL, that is once patients have overcome
the barrier of primary access to care.
Conclusions
This prospective study among patients treated for DLBCL
with R-CHOP and R-CHOP like regimens in France yields
information about the adherence to treatment and its
association with overall survival in a “real life” setting. Our
results suggest that poor adherence to treatment is
strongly associated with overall survival with a risk of
death almost four-time greater among patients with RDI
< 85% compared with those with RDI ≥ 85%, principally
during the first two-years after the initiation of the treat-
ment. About 17.5% of the whole treated patients in this
study received less than 85% of the planned treatment
which was associated with advanced age and a high risk
profile. Conversely, treatment in academic medical centres
favoured a good adherence to treatment. As these centres
have developed a telephone-based intervention by an
oncology-certified nurse to monitor patients’ treatment,
this warrants further research as a potential for the man-
agement of adverse effects. No effect of patients’ socioeco-
nomic gradient was found on either adherence to treatment
or overall survival.
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